On the stock market since 1980, it operates in the world of health and science. It has 10,800 employees. Now — the numbers.
This is an established company with proven profits.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
Executives buying with their own money is usually read as confidence in the company’s future.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Profit power and business quality lead the class.
Debt is low and cash is strong; the finances stand solid.
The price isn’t cheap next to earnings — that’s why this grade sits in the middle.
This grade is a blend: the profit side is strong, the sales tempo slow.
Clearly above the class average — a step short of the very top.
No real weak spot in any of the five subjects — a balanced report card.
The stock trades 24% below its peak. The market has trimmed its expectations for the company.
The net profit margin is 16% — still a thick cushion, though costs have been eating into it lately.
There is $791.3M in the vault; even if every debt were paid off, $374.6M would remain.
It met or beat analyst expectations in 8 of the last 8 quarters — consistency is a promise kept.
Over the last 3 years, sales grew only 2% a year on average — the report card’s higher growth grade leans on profit power instead.
The company’s market value is 51 times its annual profit. Even a small disappointment could hit the price hard.
On our five-subject report card, WST sits near the top of the class. A high grade doesn’t mean “guaranteed win” — it means “the evidence looks strong for now.”
The takeaway: WST is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s what that quality should cost.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.